ONO-7475-03 : ONO-7475 Phase 1 Study
Phase 1
- Conditions
- EGFR mutated, stage IIIB/IIIC/IV or recurrent, NSCLC, which is unsuitable for radical irradiation
- Registration Number
- JPRN-jRCT2051210045
- Lead Sponsor
- Osawa Masahiro
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Recruiting
- Sex
- All
- Target Recruitment
- 75
Inclusion Criteria
1. Patients with stage IIIB/IIIC/IV or recurrent NSCLC, which is unsuitable for radical irradiation
2. Patients with confirmed EGFR gene exon 19 deletion or EGFR gene exon 21 mutation(L858R)and who are scheduled to receive osimertinib
3. Patient has an ECOG performance status of 0-1
Exclusion Criteria
1. Patients with severe complication
2. Patients with multiple primary cancers
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Tolerability, safety
- Secondary Outcome Measures
Name Time Method